Zobrazeno 1 - 10
of 329
pro vyhledávání: '"Ferdinand C, Breedveld"'
Introduction: This post-hoc analysis explored Methotrexate (MTX) withdrawal on clinical, radiographic, and functional outcomes in patients with early rheumatoid arthritis who previously received 52 weeks of Etanercept (ETN) + MTX treatment in the COM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465ab7983dc0223fab603773c297df03
https://eprints.whiterose.ac.uk/176361/1/TORJ-15-31.pdf
https://eprints.whiterose.ac.uk/176361/1/TORJ-15-31.pdf
Publikováno v:
Clinical and Translational Science. 11:38-45
A randomized, parallel-dose study assessed the pharmacokinetics (PK) and pharmacodynamics (PD) of etanercept in 61 patients with rheumatoid arthritis (RA) who received doses from 10 mg once-weekly to 50 mg twice-weekly for 4 weeks. Empiric applicatio
Autor:
Jonathan, Kay, Monika M, Schoels, Thomas, Dörner, Paul, Emery, Tore K, Kvien, Josef S, Smolen, Ferdinand C, Breedveld, Michael H, Weisman
Publikováno v:
Annals of the Rheumatic Diseases, 77(2), 165. BMJ Publishing Group
The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force comprised an expert group of specialists in rheumatology, dermatology and gastroenterology, an
Autor:
Raffaele D'Amelio, Victoria Furer, Nico M Wulffraat, Maxime Dougados, Marc Bijl, Anna Molto, Sander van Assen, Ori Elkayam, Leo Smolar, Nancy Agmon-Levin, Annette de Thurah, Ulf Müller-Ladner, Meliha C Kapetanovic, Robert Landewé, Klaus Warnatz, Jacob M van Laar, Karen Schreiber, Christien Rondaan, James T. Walker, Ferdinand C. Breedveld, Marloes W Heijstek
Publikováno v:
RMD Open
RMD Open, 5(2). BMJ Publishing Group
Rondaan, C, Furer, V, Heijstek, M W, Agmon-Levin, N, Bijl, M, Breedveld, F C, D'Amelio, R, Dougados, M, Kapetanovic, M C, Van Laar, J M, De Thurah, A L, Landewé, R, Molto, A, Müller-Ladner, U, Schreiber, K, Smolar, L, Walker, J, Warnatz, K, Wulffraat, N M, Van Assen, S & Elkayam, O 2019, ' Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases : A systematic literature review for the 2019 update of EULAR recommendations ', RMD Open, vol. 5, no. 2, e001035 . https://doi.org/10.1136/rmdopen-2019-001035
RMD Open, 5(2). BMJ Publishing Group
Rondaan, C, Furer, V, Heijstek, M W, Agmon-Levin, N, Bijl, M, Breedveld, F C, D'Amelio, R, Dougados, M, Kapetanovic, M C, Van Laar, J M, De Thurah, A L, Landewé, R, Molto, A, Müller-Ladner, U, Schreiber, K, Smolar, L, Walker, J, Warnatz, K, Wulffraat, N M, Van Assen, S & Elkayam, O 2019, ' Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases : A systematic literature review for the 2019 update of EULAR recommendations ', RMD Open, vol. 5, no. 2, e001035 . https://doi.org/10.1136/rmdopen-2019-001035
AimTo present a systematic literature review (SLR) on efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD), aiming to provide a basis for updating the EULAR evidence-based recomm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e3ae0ba7e1982b9c80bd39f92e8bbe
https://dspace.library.uu.nl/handle/1874/391699
https://dspace.library.uu.nl/handle/1874/391699
Publikováno v:
Annals of the rheumatic diseases. 79(4)
In their correspondence, Cantini and Benucci1 voice concern regarding the recommendation of our international multidisciplinary task force on biosimilars that ‘a single switch from a bio-originator to one of its biosimilars is safe and effective.
Autor:
Jean-Yves Reginster, Peter Tugwell, Heidi Mäkinen, Ferdinand C. Breedveld, Ronald van Vollenhoven, Cyrus Cooper, Christopher J Edwards, Eric Abadie, Tore K Kvien, T. Sokka-Isler, Thierry Thomas, Olivier Bruyère, Maarten Boers, Pierre Miossec, Josef S. Smolen, Sabine Collaud Basset
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 75(7), 1268-1271. BMJ Publishing Group
Annals of the Rheumatic Diseases, 75(7), 1268-1271
Annals of the rheumatic diseases, 75(7), 1268-1271. BMJ Publishing Group
Smolen, J S, Basset, S C, Boers, M, Breedveld, F, Edwards, C J, Kvien, T K, Miossec, P, Sokka-Isler, T, van Vollenhoven, RF, Abadie, E C, Bruyere, O, Cooper, C, Makinen, H, Thomas, T, Tugwell, P & Reginster, J-Y 2016, ' Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease ', Annals of the Rheumatic Diseases, vol. 75, no. 7, pp. 1268-1271 . https://doi.org/10.1136/annrheumdis-2016-209429
Annals of the Rheumatic Diseases, 75(7), 1268-1271. BMJ Publishing Group
Annals of the Rheumatic Diseases, 75(7), 1268-1271
Annals of the rheumatic diseases, 75(7), 1268-1271. BMJ Publishing Group
Smolen, J S, Basset, S C, Boers, M, Breedveld, F, Edwards, C J, Kvien, T K, Miossec, P, Sokka-Isler, T, van Vollenhoven, RF, Abadie, E C, Bruyere, O, Cooper, C, Makinen, H, Thomas, T, Tugwell, P & Reginster, J-Y 2016, ' Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease ', Annals of the Rheumatic Diseases, vol. 75, no. 7, pp. 1268-1271 . https://doi.org/10.1136/annrheumdis-2016-209429
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial methodology to comment on the new draft ‘Guideline
Autor:
Stefan Florentinus, Ferdinand C. Breedveld, I. Sainsbury, Hartmut Kupper, Edward C. Keystone, Y. Li
Publikováno v:
RMD Open
Objective To evaluate long-term clinical, functional and radiographic outcomes in an open-label extension (OLE) study in patients with rheumatoid arthritis (RA) receiving adalimumab monotherapy or adalimumab+methotrexate following attainment of low d
Autor:
Ferdinand C. Breedveld, Alexandre Sepriano, Klaus P Machold, Emilio Martín-Mola, Daniel Aletaha, Farideh Alasti, Robert Landewé, David S. Pisetsky, Dimitri Boumpas, Peter E. Lipsky, Martin Aringer, Maurizio Cutolo, Gerd R Burmester, Wolfgang Ebner, Désirée van der Heijde, Tanja Stamm, Hendrik Schulze-Koops, Tom W J Huizinga, Paul P. Tak, Josef S Smolen, Winfried Graninger, Georg Schett
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Arthritis research & therapy, 20(1):174. BioMed Central
Arthritis Research & Therapy
Arthritis Research and Therapy
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)
Consejería de Sanidad de la Comunidad de Madrid
Arthritis research & therapy, 20(1):174. BioMed Central
Arthritis Research & Therapy
Arthritis Research and Therapy
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)
Background In the present study, we explored the effects of immediate induction therapy with the anti-tumour necrosis factor (TNF)α antibody infliximab (IFX) plus methotrexate (MTX) compared with MTX alone and with placebo (PL) in patients with very
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::248bdd175334d0213b2e4fcf29588620
https://hdl.handle.net/20.500.12530/35909
https://hdl.handle.net/20.500.12530/35909
Publikováno v:
Clinical and Translational Science
A randomized, parallel‐dose study assessed the pharmacokinetics (PK) and pharmacodynamics (PD) of etanercept in 61 patients with rheumatoid arthritis (RA) who received doses from 10 mg once‐weekly to 50 mg twice‐weekly for 4 weeks. Empiric appl
Autor:
I. Sainsbury, Désirée van der Heijde, Ronald F van Vollenhoven, Hartmut Kupper, Kun Chen, Ferdinand C. Breedveld, Josef S Smolen, Edward C. Keystone, Paul Emery, Arthur Kavanaugh, Stefan Florentinus
Publikováno v:
RMD open, 3(2). BMJ Publishing Group
RMD Open, 3(2):e000445. BMJ Publishing Group
Keystone, E C, Breedveld, F C, Heijde, D V D, Van Vollenhoven, R F, Emery, P, Smolen, J S, Sainsbury, I, Florentinus, S, Kupper, H, Chen, K & Kavanaugh, A 2017, ' Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone ', RMD Open, vol. 3, no. 2, e000445 . https://doi.org/10.1136/rmdopen-2017-000445
RMD Open
RMD Open, 3(2):e000445. BMJ Publishing Group
Keystone, E C, Breedveld, F C, Heijde, D V D, Van Vollenhoven, R F, Emery, P, Smolen, J S, Sainsbury, I, Florentinus, S, Kupper, H, Chen, K & Kavanaugh, A 2017, ' Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone ', RMD Open, vol. 3, no. 2, e000445 . https://doi.org/10.1136/rmdopen-2017-000445
RMD Open
Objective To evaluate the achievement of comprehensive disease control (CDC) following 1 year of treatment with adalimumab+methotrexate versus methotrexate alone and whether early achievement of remission (at week 24 or 26) is associated with CDC at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6021f3bde57977a3d8afa9e3da57825
https://pure.amc.nl/en/publications/achieving-comprehensive-disease-control-in-patients-with-early-and-established-rheumatoid-arthritis-treated-with-adalimumab-plus-methotrexate-versus-methotrexate-alone(924de577-3758-40b0-8cb4-787dc46025a9).html
https://pure.amc.nl/en/publications/achieving-comprehensive-disease-control-in-patients-with-early-and-established-rheumatoid-arthritis-treated-with-adalimumab-plus-methotrexate-versus-methotrexate-alone(924de577-3758-40b0-8cb4-787dc46025a9).html